Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accumulated Expenses: 2020-2025

Historic Accumulated Expenses for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Mar 2025 value amounting to $2.9 million.

  • China SXT Pharmaceuticals' Accumulated Expenses rose 11.77% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 11.77%. This contributed to the annual value of $2.9 million for FY2025, which is 6.11% up from last year.
  • China SXT Pharmaceuticals' Accumulated Expenses amounted to $2.9 million in FY2025, which was up 6.11% from $2.8 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Accumulated Expenses registered a high of $3.5 million during FY2022, and its lowest value of $2.8 million during FY2024.
  • Moreover, its 3-year median value for Accumulated Expenses was $2.9 million (2025), whereas its average is $2.9 million.
  • In the last 5 years, China SXT Pharmaceuticals' Accumulated Expenses skyrocketed by 36.19% in 2021 and then declined by 11.89% in 2024.
  • Yearly analysis of 5 years shows China SXT Pharmaceuticals' Accumulated Expenses stood at $3.0 million in 2021, then increased by 15.84% to $3.5 million in 2022, then dropped by 10.98% to $3.1 million in 2023, then fell by 11.89% to $2.8 million in 2024, then grew by 6.11% to $2.9 million in 2025.